Business
Pfizer and BioNTech Receive Health Sciences Authority Approval for SARS-CoV-2 Sublineage LP.8.1-Adapted Monovalent COVID-19 Vaccine in Singapore
Pfizer Singapore and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Health Sciences Authority has approved the companies' LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1; COVID-19 Vaccine, mRNA) for use in individuals 6 months of age and older, according to official recommendations*. This marks Singapore as the first country in Southeast Asia to receive full approval for the latest COVID-19 vaccine.
About this update from Pfizer, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"The updated COVID-19 vaccine is expected to be available in Singapore at selected polyclinics and private general practitioner (GP) clinics in October 2025 for individuals 6 months of age and older.","length":199,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":199,"olType":false},{"type":"text","content":"SINGAPORE, Oct. 24, 2025 /PRNewswire/ -- Pfizer Singapore and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Health Sciences Authority has approved the companies' LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1; COVID-19 Vaccine, mRNA) for use in individuals 6 months of age and older, according to official recommendations*. This marks Singapore as the first country in Southeast Asia to receive full approval for the latest COVID-19 vaccine.","length":493,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Pfizer Singapore,BioNTech)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Pfizer Singapore,BioNTech)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":165,"url":"https://media.zenfs.com/en/prnewswire.com/5d7247fcb45e4ae4630d53fd72ed8ebe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wo6SrBCyIYgJ8CCeYFmPeg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI5MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/5d7247fcb45e4ae4630d53fd72ed8ebe","width":400,"height":165}},"href":"https://mma.prnewswire.com/media/2803667/5579200/Pfizer_Color_RGB_2021_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The LP.8.1 sublineage selection is based on guidance from the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and World Health Organization (WHO) which stated that LP.8.1 is the preferred sublineage of a monovalent JN.1-lineage-based COVID-19 vaccine for use in the U.S. beginning in fall 2025.[1]","length":322,"tagName":"p"},{"type":"text","content":""Pfizer remains steadfast in our commitment to protecting public health through science and innovation. The approval of this updated LP.8.1-adapted monovalent COVID-19 vaccine marks another important milestone in our ongoing efforts to provide communities with timely access to protection. We echo the government's call for proactive healthcare and prevention measures." said Ms. Deborah Seifert, Clu...